Ribociclib Succinate
Ribociclib succinate works by blocking the activity of proteins called CDK4 and CDK6 that control how fast cells grow. Blocking these proteins may slow or stop the growth of cancer cells. Ribociclib succinate is a type of targeted therapy drug called a kinase inhibitor. It is a small-molecule drug (a drug that can enter cells easily).
FDA label information for this drug is available at DailyMed.
Use in Cancer
Ribociclib succinate is approved to be used with other drugs to treat:
- breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-). It is used:
- with an aromatase inhibitor in women who have stage II or stage III early breast cancer that is at high risk of coming back
- with an aromatase inhibitor in women whose cancer has spread and has not been treated with hormone therapy
- with fulvestrant in women whose cancer has spread and has not been treated with hormone therapy or whose cancer got worse during treatment with hormone therapy
Ribociclib succinate is also available in a combination pack with letrozole. Ribociclib succinate and letrozole may work better together than when either is given alone. For more information that may apply to this combination pack, see the Drug Information Summary for Ribociclib Succinate and Letrozole.
Ribociclib succinate is also being studied in the treatment of other types of cancer.
More About Ribociclib Succinate
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Ribociclib Succinate - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
A Safer, Better Treatment Option for Some Younger Women with Breast Cancer
Targeted Therapy to Treat Cancer
Combo of Ribociclib, Letrozole Improves Survival in Advanced Breast Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Ribociclib Succinate - Check for trials from NCI's list of cancer clinical trials now accepting patients.